Skip Navigation

Annals of Oncology 2007 18(Supplement 6):vi35-vi41; doi:10.1093/annonc/mdm222
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bareschino, M.
Right arrow Articles by Ciardiello, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bareschino, M.
Right arrow Articles by Ciardiello, F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

small molecule kinasi inhibitors

Erlotinib in cancer treatment

MA Bareschino, C Schettino, T Troiani, E Martinelli, F Morgillo and F Ciardiello*

Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery "F. Magrassi and A. Lanzara", Second University of Naples, School of Medicine, Naples, Italy

* Correspondence to: F. Ciardiello, Cattedra di Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale ‘‘F. Magrassi e A. Lanzara’’, Seconda Università degli Studi di Napoli, Via S. Pansini, 5, 80131 Naples, Italy. Tel: +39-081-5666745; Fax: 39-081-5666728; E-mail: fortunato.ciardiello{at}unina2.it

The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase (TK) receptor that is frequently expressed in many epithelial tumors. The signaling pathways of EGFR is involved in cancer cell proliferation, apoptosis, angiogenesis, invasions and metastasis. The EGFR was the first receptor to be proposed for cancer therapy and two EGFR-targeted pharmacological approaches have been successfully developed: monoclonal antibodies and small-molecule inhibitor of the EGFR TK enzymatic activity. Erlotinib is a quinazoline derivative that selectively and reversibly inhibits the TK activity of EGFR. Erlotinib, on the basis of the results of a large randomized phase III clinical trial (BR21) in which show a survival benefit versus placebo-treated patients, received regular approval for the treatment of advanced non-small-cell lung cancer (NSCLC) patients after failure a platinum-containing chemotherapy. Erlotinib was recently approved in combination with gemcitabine chemotherapy for the treatment of advanced pancreatic cancer, and continues to be investigated in a number of tumor types. Furthermore, it has been investigated the role of factors that would predict the efficacy of erlotinib treatment, including anatomoclinical, pathologic and molecular features. This review will focus on the clinical results available with erlotinib in the treatment of NSCLC, pancreatic, head and neck and other tumor types.

Key words: EGFR pathways, erlotinib, NSCLC, pancreatic cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.